Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...
Evolution AB (publ) reported disappointing Q3 2025 results, with net sales down 2.4% and significant challenges in Asia, causing an 8% stock drop. Asia, accounting for 37% of revenue, faces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback